Tamibarotene Plus Venetoclax/Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

NCT04905407 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

66

Enrollment

INDUSTRY

Sponsor class

Stopped As per sponsor decision, the study was terminated.

Conditions

Acute Myeloid Leukemia

Interventions

DRUG: Tamibarotene
DRUG: Venetoclax
DRUG: Azacitidine

Sponsor

Syros Pharmaceuticals